Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orbec with prednisone for acute gastrointestinal graft-versus-host disease
2010-022247-37Phase 3Active
- Sponsor
- Soligenix
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in graft-versus-host disease (GVHD) and gastrointestinal graft versus host disease comparing Orbec + prednisone with Placebo + prednisone (2 arms). Primary endpoint: GVHD treatment failure during 80-day study period. Started Sep 2010; status: active.
02
Drugs
beclomethasone dipropionate
03
Conditions
graft-versus-host disease (GVHD)gastrointestinal graft versus host disease
Beyond the preview
Go deeper on 2010-022247-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022247-37.